• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

J&J-led coali­tion launch­es a land­mark ef­fi­ca­cy study for an HIV mo­sa­ic vac­cine

8 years ago
R&D

Look­ing to cure Type 1 di­a­betes, in­vestors front $114M to launch a pi­o­neer­ing hu­man study at Sem­ma

8 years ago
People
Financing

Am­gen pulls ahead in sprint to­wards CGRP ap­proval with promis­ing PhI­II mi­graine da­ta

8 years ago
R&D

J&J dis­putes re­port it’s drop­ping JLabs plans for UK; Take­da takes Zi­ka vac­cine in­to PhI

8 years ago
News Briefing

New back­ers Sofinno­va and Scopia bring Y-mAb's round to $80M for an­ti-can­cer drugs

8 years ago
Financing

Uni­ver­si­ty was tipped off to pos­si­ble unau­tho­rized tri­als of her­pes vac­cine

8 years ago
R&D

Blue­bird bio or­ches­trates a se­ries of deals and a buy­out to guar­an­tee gene ther­a­py man­u­fac­tur­ing

8 years ago
Deals
Cell/Gene Tx

Fra­zier backs MavuPhar­ma’s $20M round, brings in heavy­weight ex­ecs to lead

8 years ago
Financing
Startups

In lat­est deal, Melin­ta ex­e­cutes $270M pact to buy out Med­i­cines Co’s in­fec­tious dis­ease group

8 years ago
Pharma

Doug Williams ups the ante at Co­di­ak Bio to $168.5M in a dri­ve to first hu­man study

8 years ago
People
Financing

Re­gen­eron and Deci­bel aren’t just col­lab­o­rat­ing: They want to cre­ate a whole new part­ner­ing mod­el

8 years ago
Startups
R&D

Vir chief Scan­gos picks Her­bert ‘Skip’ Vir­gin to run R&D; Arde­lyx forges $160M deal with Ky­owa Hakko Kirin

8 years ago
News Briefing

RA backs Mede­or’s $57M round as re­searchers fast for­ward to PhI­II

8 years ago
Financing

Phar­ma's bro­ken busi­ness mod­el: An in­dus­try on the brink of ter­mi­nal de­cline

8 years ago
R&D
Biotech Voices

Pfiz­er, Mer­ck KGaA run in­to a se­vere set­back as PD-L1 drug Baven­cio fails in PhI­II gas­tric can­cer study

8 years ago
R&D

Strike two: Au­ris shares crushed again as its sec­ond PhI­II pro­gram fails to de­liv­er

8 years ago
R&D

Af­ter build­ing a rep as an ar­chi­tect of ex­per­i­ments, Rx­Cel­er­ate plants its flag in Amer­i­ca

8 years ago
People
Outsourcing

Syn­thet­ic bi­ol­o­gy pi­o­neer Syn­thorx re­cruits Cleave's Lau­ra Shawver for top po­si­tion

8 years ago
People

How much is an FDA short­cut worth to drug de­vel­op­ers hus­tling to an OK? Hold­ing steady at $125M, cash

8 years ago
Pharma

Roiled by fi­nan­cial tur­moil, Teva's CEO boots R&D chief, top ex­ecs in C-suite over­haul

8 years ago
People
R&D

In­trex­on taps new COO, CBO in ex­ec­u­tive reshuf­fle; De­nali tar­gets up to $182M in IPO

8 years ago
News Briefing

Bio­gen’s an­swer to Alk­er­mes’ Tec­fidera threat? Buy it, but don’t spend too much

8 years ago
Pharma

Cat­a­lyst heads back to the FDA in search of an elu­sive OK af­ter Fir­dapse scores high in new PhI­II

8 years ago
R&D

As­traZeneca teams with Chi­na-owned fund to launch a new bio­phar­ma drug de­vel­op­ment com­pa­ny

8 years ago
Financing
China
First page Previous page 1066106710681069107010711072 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.